- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Obicetrapib given with high-intensity statins reduces LDL-C by 50 percent: Study
USA: Obicetrapib at doses of 5 and 10 mg largely reduced LDL-C in patients treated with high-intensity statins, according to results from the Rose Clinical Trial. In addition, obicetrapib produced robust decreases in ApoB and Non-HDL-C and increases in HDL-C compared to placebo.
The findings of the study were presented at the American Heart Association Scientific Sessions 2021.
Obicetrapib is a member of the cholesteryl ester transfer protein (CETP) inhibitor class, which had fallen out of favor after several disappointments with previous drugs in this class. These agents were initially developed for their ability to raise HDL cholesterol, which was thought to be beneficial. But that approach has now been virtually abandoned after several studies failed to show a link between raising HDL and a reduction in subsequent cardiovascular events.
However, obicetrapib, which is said to be the most potent CETP inhibitor to date, has also been shown to produce impressive LDL reductions, and it's this important data that has caused several lipid experts to want to continue its development.
The recent study included patients (n=120) with an LDL-C ≥70 mg/dL, despite treatment with high-intensity statins, who were randomized to treatment with obicetrapib 5 or 10 mg or a matching placebo for 8 weeks.
The primary endpoint was the difference between groups in percent change in LDL-C from baseline to week 8.
Key findings include:
- Patients had a median LDL-C of 88 mg/dL at baseline.
- Compared with placebo, obicetrapib produced a greater dose-dependent lowering of LDL-C (up to 50.8%), which was comparable between PUC and Friedewald measures.
- Obicetrapib also produced a greater lowering of apoB (up to 29.8%) and non-HDL-C (up to 44.4%) and raising of HDL-C (up to 165%) in a dose-dependent fashion compared with placebo. (Table).
- Fewer patients in the OBI arms (26%) experienced treatment-emergent adverse events than in the placebo arm (48%).
- No patients in either OBI arm experienced a treatment-emergent SAE.
- There were no clinically significant changes in laboratory parameters, vital signs, or physical examinations in any study group.
New data show that obicetrapib reduces LDL by 50% when given in addition to high-intensity statins, which could place it as competition for PCSK9 inhibitors or the new agent, inclisiran, but with the advantage of oral dosing.
The drug was in development by Amgen, but the company decided to discontinue its development in 2017 after disappointing results had been seen with several other CETP inhibitors and interest in this class of agent was waning.
"Obicetrapib at doses of 5 and 10 mg produced robust decreases in LDL-C, ApoB and Non-HDL-C and increases in HDL-C compared to placebo in patients treated with high-intensity statins." the authors concluded.
Reference:
Obicetrapib Lowers LDL-C in Patients Taking High Intensity Statins: Results From Rose Clinical Trial
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751